FGFR2 expression relates to subtype-specific tumour microenvironment (TIME) during luminal breast cancer evolution.

ABSTRACT:

Background

Fibroblast growth factor receptor 2 (FGFR2) is an oncogenic driver in luminal breast cancer (BCa), with emerging evidence linking it to tumour immune microenvironment (TIME) modulation. While FGFR2's role in endocrine resistance is established, its potential involvement in shaping immune infiltration-particularly in the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)-remains underexplored.

Methods

This retrospective study analysed 99 BCa specimens collected between 2004-2019. Immunohistochemistry was used to assess FGFR2 expression and immune markers (CD8, CD68, CD163, FOXP3). Clinical and pathological variables were evaluated, and immune cell densities were compared across disease stages and BCa subtypes (luminal vs. non-

SUBMITTER: Solek J 

PROVIDER: S-EPMC12463615 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature